OYST News and Press, Oyster Point Pharma Inc. From 12/23/19

PRINCETON, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

PRINCETON, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jef...

This year was another crucial one for biotech thanks in large part to initial public offerings (IPOs), merger and acquisition (M&A) activity and niche therapeutic areas garnering attention. During the year, while the number of IPOs slowed in comparison to last year, some of the largest M...